Skip Over Navigation Links



TRND Information

Industry Acquires First Drug Candidate from TRND Program

Red blood cells showing sickling from sickle cell disease.

On July 9, 2014, NIH announced that biopharmaceutical company Baxter International has acquired a drug candidate developed by NCATS' Therapeutics for Rare and Neglected Diseases (TRND) researchers and collaborators. The small molecule, Aes-103, is designed to treat sickle cell disease, a genetic blood disorder that affects millions worldwide, including approximately 100,000 people in the United States — among them, 1 in 500 African-Americans.

NIH News Release

NCATS Director’s Message

Baxter International News Release

TRND Aes-103 Project Page

TRND Fact Sheet

Learn how you can participate in clinical trials - National Institutes of Health